Perspective Therapeutics Announces the Awarding of a $1 million Collaborative Grant to King’s College London to Support Radiobiology Research of Alpha Particle Therapy for Cancer
08 Março 2023 - 9:30AM
Perspective Therapeutics, Inc. (formerly known as “Isoray, Inc.”)
(NYSE AMERICAN: CATX), a precision oncology company developing
alpha-particle therapies and complementary diagnostic imaging
agents and an innovator in seed brachytherapy powering expanding
treatment options for multiple cancers, announced the awarding of a
$1 million research grant from the Medical Research Council (MRC),
part of UK Research and Innovation (UKRI) (www.ukri.org), to
collaborator Samantha Terry PhD, Associate Professor (Senior
Lecturer) at King’s College London.
“My research is focused on the interactions of
radiation with cells at a fundamental level. We are seeing that the
use of radionuclides that deliver alpha particle and Auger electron
emissions, often referred to as high linear energy interactions,
have the potential to be transformative for cancer therapy” said
Dr. Terry. “This award provides an opportunity to develop a more
detailed understanding of these interactions toward a goal of
realizing the full potential of radionuclides such as 212Pb for
cancer patients. We are grateful to the Medical Research Council
and incredibly excited about the collaboration with the Perspective
Therapeutics team.”
Neuroendocrine cancers begin in
hormone-releasing neuroendocrine cells and can occur anywhere in
the body including the lungs, appendix, small intestine, rectum and
pancreas. Although rare, they are very hard to treat; therefore
there is a need for novel options to treat both the original tumor
and cancer cells that have spread throughout the body. Under the
project, Perspective Therapeutics’ scientists will collaborate on
radiobiology research, and provide isotopes and peptide precursors.
Perspective Therapeutics is supporting a graduate student working
toward a doctorate in radiobiology under the guidance of Dr.
Terry.
“We’re delighted to see the grant from the UK’s
Medical Research Council (MRC) go to our collaborator Dr. Samantha
Terry,” said Michael Schultz, Perspective Therapeutics’ Chief
Scientific Officer. “We are continuously working towards advancing
the understanding of how our lead drug candidate [212Pb]VMT-α-NET
can potentially transform the treatment landscape for
neuroendocrine cancers. The decay series of 212Pb results in the
emission of high energy alpha-particle emissions that travel short
distances in tissues. By coupling 212Pb with high precision peptide
cancer cell specific receptor-directed radioligands, a more precise
delivery of these high energy particles to tumors can be realized.
We believe the mechanism of action creates an ideal agent for
precise cancer killing while sparing nearby healthy tissue. We are
excited to be part of the research project and providing support
for thought leading scientists in this area of research.”
About Perspective Therapeutics, Inc.Perspective
Therapeutics, Inc., formerly known as Isoray, Inc., is a medical
technology and radiopharmaceutical company that is pioneering
advanced treatment applications for cancers throughout the body.
The Company is the sole producer of Cesium-131 brachytherapy seeds
and has a proprietary technology that utilizes the isotope lead-212
to deliver powerful alpha radiation specifically to cancer cells
via specialized targeting peptides. The Company is also developing
complementary imaging diagnostics that incorporate the same
targeting peptides which provide the opportunity to personalize
treatment and optimize patient outcomes. This “theranostic”
approach enables the ability to see the specific tumor and then
treat it to potentially improve efficacy and minimize toxicity
associated with many other types of cancer treatments.
Perspective Therapeutics’ melanoma (VMT01) and neuroendocrine
tumor (VMT-α-NET) programs are entering Phase 1/2a imaging and
therapy trials for the treatment of metastatic melanoma and
neuroendocrine tumors at several leading academic institutions. The
Company has also developed a proprietary lead-212 generator to
secure isotope supply for clinical trial and commercial
operations.
For more information, please visit the Company’s website at
www.perspectivetherapeutics.com.
Safe Harbor StatementStatements in this news
release about Perspective Therapeutics, Inc.’s (“Perspective”) and
its wholly-owned subsidiary Viewpoint Molecular Targeting, Inc.’s
(“Viewpoint,” and together with Perspective, the “Company”) future
expectations, including: the functionality and capabilities of the
Company’s therapies including its targeted alpha-particle
radiotherapy; the potential size of the commercial market for the
Company’s treatment programs; the Company’s expectations, beliefs,
intentions, and strategies regarding the future; and all other
statements in this news release, other than historical facts, are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (“PSLRA”). This statement
is included for the express purpose of availing the Company of the
protections of the safe harbor provisions of the PSLRA. It is
important to note that actual results and ultimate corporate
actions could differ materially from those in such forward-looking
statements based on such factors as whether the research to be
conducted with the grant money discussed in this news release will
be successful and whether the results will support the Company’s
expectations as to the benefits of its lead radiation therapy
candidate; the ability to raise ongoing capital to fund added costs
of research and development related to the Company’s business; the
ability of the Company to manage growth and successfully integrate
its businesses; whether the Company can maintain its key employees;
the risk that the recent merger disrupts current plans and
operations; the outcome of any legal proceedings that may be
instituted against the Company following consummation of the
merger; whether the Company’s anticipated product pipeline is
achieved; ; whether the anticipated benefits of the Company’s
therapies are realized; training and use of the Company’s products;
market acceptance and recognition of the Company’s products; the
Company’s ability to enforce its intellectual property rights;
whether ongoing patient results are favorable and in line with the
conclusions of clinical studies and initial patient results;
successful completion of future research and development
activities; whether we, our distributors, and our customers will
successfully obtain and maintain all required regulatory approvals
and licenses to market, sell, and use our products in their various
forms; the procedures and regulatory requirements mandated by the
FDA for animal trials, human trials, clinical studies, Phase I and
II approvals and 510(k) approval and reimbursement codes; changes
in applicable laws and regulations; and other risks detailed from
time to time in the Company’s reports filed with the SEC.
Unless required to do so by law, we undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise. For
more information regarding risks and uncertainties that could
affect the Company’s results of operations or financial condition,
please review the definitive Proxy Statement filed on November 7,
2022, and our Form 10-K filed on September 28, 2022, with the
SEC.
Contacts
Perspective Therapeutics Investor Relations: Chuck Padala (917) 741-7792
IsoRay (AMEX:ISR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
IsoRay (AMEX:ISR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024